Achilles Therapeutics PLC
(FRA:698)
€
0.71
0 (0%)
Market Cap: 30.32 Mil
Enterprise Value: -69.29 Mil
PE Ratio: 0
PB Ratio: 0.27
GF Score: 34/100 - Achilles Therapeutics PLC at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) TranscriptApr 24, 2023
- Achilles Therapeutics PLC at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 14, 2023
- Achilles Therapeutics PLC at Eqt Life Sciences BioCapital Europe TranscriptMar 09, 2023
- Achilles Therapeutics PLC at JPMorgan Healthcare Conference TranscriptJan 12, 2023
- Achilles Therapeutics PLC ESMO IO Webcast Call TranscriptDec 06, 2022
- Achilles Therapeutics PLC at Bank of America Healthcare Conference TranscriptMay 11, 2022
- Achilles Therapeutics PLC to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting - Fireside Chat TranscriptApr 14, 2022
- Achilles Therapeutics PLC at Needham Healthcare Conference (Virtual) TranscriptApr 12, 2022
- Achilles Therapeutics PLC SITC and Corporate Update Call TranscriptNov 12, 2021
Achilles Therapeutics PLC to Highlight TRACERx Study Presentations from the 2022 AACR Annual Meeting - Fireside Chat Transcript
Apr 14, 2022 / 02:30PM GMT
Release Date Price:
€2.22
(-0.89%)
Lee M. Stern
Achilles Therapeutics plc - VP of IR & External Communications
Presentations from the 2022 AACR Annual Meeting - Fireside Chat
Apr 14, 2022 / 02:30PM GMT
=====================
Corporate Participants
=====================
* Charles Swanton
Achilles Therapeutics plc - Founder
* Iraj Ali
Achilles Therapeutics plc - CEO & Director
* Lee M. Stern
Achilles Therapeutics plc - VP of IR & External Communications
* Sergio A. Quezada
Achilles Therapeutics plc - Founder & Chief Scientific Officer
=====================
Conference Call Participants
=====================
* Joseph Michael Catanzaro
Piper Sandler & Co., Research Division - Director & Senior Biotech Analyst
=====================
-
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)